Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.
SUPN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Supernus Pharmaceuticals Inc. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 91th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Supernus Pharmaceuticals Inc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.44 years, is 0.8% -- higher than 88.25% of stocks in our DCF forecasting set.
Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 14.04% of tickers in our DCF set.
As a business, Supernus Pharmaceuticals Inc experienced a tax rate of about 17% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 73.85% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Supernus Pharmaceuticals Inc? See OMI, RDY, ANIP, AMS, and CYH.
An issue dogging Supernus (SUPN) is potential generic competition for Trokendi XR in 2023 (p. 28). Trokendi XR has been Supernus' long-term revenue driver since 2014. It made up 73% (p. 19) of the company's net product sales for the first six months of 2020. Any challenge to its earnings...
Out of Ignorance on Seeking Alpha | September 29, 2020
Supernus (SUPN) is a long-term holding of mine that I first wrote about in May shortly after the company had acquired the CNS assets of US WorldMeds and before any 2020 financial data had been released. I discussed how this type of acquisition seemed like a prudent use of free...
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex Inc. and Apotex Corp. (collectively, Apotex) for infringement of nine patents covering its antiepileptic drug Oxtellar XR®. The Complaint – filed in the U.S. District Court for the District of New Jersey – alleges that Apotex infringed Supernus's Oxtellar XR patents by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Oxtellar XR prior to the expiration of Supernus's patents. Filing its Complaint within 45 days of receiving Apotex’s Paragraph IV certification not...
In this article we will take a look at whether hedge funds think Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]